Keenova Therapeutics plc Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 26, 2025	Q2 FY2025 As of Jun 27, 2025	Q1 FY2025 As of Mar 28, 2025	Q4 FY2024 As of Dec 27, 2024	Q3 FY2024 As of Sep 27, 2024	Q2 FY2024 As of Jun 28, 2024	Q1 FY2024 As of Mar 29, 2024	Q4 FY2023 As of Dec 29, 2023	Q3 FY2023 As of Sep 29, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 30, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jul 1, 2022	Q1 FY2022 As of Apr 1, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 24, 2021
Assets
Current Assets:
Cash and cash equivalents
Accounts receivable, less allowance for doubtful accounts of $1.2 and $1.1
Inventories
Prepaid expenses and other current assets
Assets Held-for-sale, Not Part of Disposal Group, Current
Assets held for sale
Total current assets

Property, plant and equipment, net
Goodwill
Intangible assets, net
Deferred income taxes
Ordinary shares, shares issued (in shares)
Predecessor Reorganization
Successor
Successor
Ordinary A
Ordinary Shares
Total ordinary shares, shares issued (in shares)

Ordinary shares, shares authorized (in shares)
Predecessor Reorganization
Successor
Successor
Ordinary A
Ordinary Shares
Total ordinary shares, shares authorized (in shares)

Common Stock, Shares, Outstanding
Predecessor Reorganization
Successor
Successor
Ordinary A
Ordinary Shares
Total common Stock, Shares, Outstanding

Ordinary shares, par value (in usd per share)
Predecessor Reorganization
Successor
Successor
Ordinary A
Ordinary Shares
Total ordinary shares, par value (in usd per share)

Treasury Stock, Common, Shares
Ordinary shares held in treasury at cost
Other assets
Long-term assets of disposed business
Total Assets
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt
Accounts payable
Accrued payroll and payroll-related costs
Accrued interest
Opioid-Related Litigation Settlement liability
Acthar Gel-Related Settlement
Accrued rebates and returns
Accrued and other current liabilities
Current liabilities of disposed business
Liabilities held for sale
Total current liabilities
Long-term debt
Opioid-Related Litigation Settlement
Acthar Gel-Related Settlement
Pension and postretirement benefits
Environmental liabilities
Deferred Tax Liabilities, Gross
Other Noncurrent Liabilities
Total deferred Tax Liabilities, Gross

Deferred income taxes
Other income tax liabilities
Other liabilities
Liabilities subject to compromise
Long-term liabilities of disposed business
Total Liabilities
Ordinary A shares
Predecessor Reorganization
Successor
Successor
Total ordinary A shares

Ordinary A shares, shares outstanding (in shares)
Shareholders' Equity:
Preferred Stock, Value, Outstanding
Predecessor Reorganization
Successor
Successor
Total preferred Stock, Value, Outstanding

Ordinary A shares, €1.00 par value, 40,000 authorized; none issued or outstanding
Preferred shares, $0.001 par value, 3,000,000,000,000 authorized; none issued and outstanding
Ordinary shares
Predecessor Reorganization
Successor
Successor
Ordinary A
Ordinary Shares
Total ordinary shares

Preferred shares, par value (in usd per share)
Predecessor Reorganization
Successor
Successor
Total preferred shares, par value (in usd per share)

Preferred shares, shares authorized (in shares)
Predecessor Reorganization
Successor
Successor
Total preferred shares, shares authorized (in shares)

Preferred shares, shares issued (in shares)
Predecessor Reorganization
Successor
Successor
Total preferred shares, shares issued (in shares)

Preferred shares, shares outstanding (in shares)
Predecessor Reorganization
Successor
Successor
Total preferred shares, shares outstanding (in shares)

Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total Shareholders' Equity

Total Liabilities and Shareholders' Equity
Ordinary A shares, par value (in eur per share)
Ordinary A shares, shares authorized (in shares)
Ordinary A shares, shares issued (in shares)
Ordinary A shares, shares outstanding (in shares)

Comments